Zydus Lifesciences Gets USFDA Approval for Ibuprofen-Famotidine Tablets

Zydus Lifesciences, a global health care company focused solely on affordable medicines, has received final USFDA approval for Ibuprofen and Famotidine tablets, 800 mg/26.6 mg. The compound, marketed in the U.S. under the brand Duexis, contains two active ingredients for attacking specific malady in rheumatoid arthritis candidates.

The sites of action of ibuprofen and famotidine, a selective antagonistic inhibitor of histamine H2 receptors used in patients with rheumatoid arthritis and osteoarthritis, differ and thus relieve specific symptoms from both disorders. Famotidine reduces the risk of upper gastrointestinal ulcers, i.e., gastric and duodenal ulcers, in ibuprofen users in their long-term management.

Zydus Lifesciences will make medicines containing Ibuprofen and Famotidine in this modern plant located in the SEZ of Ahmedabad, India.

This approval actually expands the company's U.S. portfolio further, where the combined cubes proved to garner the annual total of about USD 3.6 million till date, as reported by IQVIAS data. Zydus Lifesciences, with vast expertise in manufacturing high-quality generic and branded drugs, is quite well placed to meet the emerging demand for effective therapies across developed and emerging markets.

With this approval, Zydus Lifesciences aims at further consolidation of its presence on the global pharmaceutical map as an option of utmost importance for addressing the diverse needs of arthritis with minimized gastrointestinal risk.